[go: up one dir, main page]

WO2009148252A3 - Peptide de ciblage d’accident cérébro-vasculaire et applications correspondantes - Google Patents

Peptide de ciblage d’accident cérébro-vasculaire et applications correspondantes Download PDF

Info

Publication number
WO2009148252A3
WO2009148252A3 PCT/KR2009/002937 KR2009002937W WO2009148252A3 WO 2009148252 A3 WO2009148252 A3 WO 2009148252A3 KR 2009002937 W KR2009002937 W KR 2009002937W WO 2009148252 A3 WO2009148252 A3 WO 2009148252A3
Authority
WO
WIPO (PCT)
Prior art keywords
stroke
targeting peptide
present
targeting
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/002937
Other languages
English (en)
Korean (ko)
Other versions
WO2009148252A2 (fr
WO2009148252A9 (fr
Inventor
이병헌
김인산
한형수
유정수
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of KNU
Original Assignee
Industry Academic Cooperation Foundation of KNU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Academic Cooperation Foundation of KNU filed Critical Industry Academic Cooperation Foundation of KNU
Priority to US12/995,934 priority Critical patent/US8748398B2/en
Publication of WO2009148252A2 publication Critical patent/WO2009148252A2/fr
Publication of WO2009148252A9 publication Critical patent/WO2009148252A9/fr
Publication of WO2009148252A3 publication Critical patent/WO2009148252A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un peptide de ciblage d’accident cérébro-vasculaire et des applications correspondantes. Plus particulièrement, la présente invention concerne un peptide de ciblage d’accident cérébro-vasculaire caractérisé en ce qu’il est représenté par une séquence d’acides aminés choisi parmi le groupe comprenant SEQ. ID 1 à SEQ ID 4. La présente invention concerne également des applications pour ce peptide de ciblage d’accident cérébro-vasculaire. Le peptide selon la présente invention est caractérisé en ce qu’il se lie de manière spécifique à des cellules d’accident cérébro-vasculaire dans un corps vivant. Ainsi il peut avantageusement être utilisé dans des marqueurs et des trousses de diagnostic d’accident cérébro-vasculaire, et des préparation d’administration de médicaments et des préparations pharmaceutiques de ciblage d’accident cérébro-vasculaire ainsi que dans des préparation d’imagerie d’accident cérébro-vasculaire.
PCT/KR2009/002937 2008-06-02 2009-06-02 Peptide de ciblage d’accident cérébro-vasculaire et applications correspondantes Ceased WO2009148252A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/995,934 US8748398B2 (en) 2008-06-02 2009-06-02 Stroke-targeting peptide and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0051555 2008-06-02
KR1020080051555A KR101110758B1 (ko) 2008-06-02 2008-06-02 뇌졸중 표적용 펩티드 및 이의 용도

Publications (3)

Publication Number Publication Date
WO2009148252A2 WO2009148252A2 (fr) 2009-12-10
WO2009148252A9 WO2009148252A9 (fr) 2010-04-01
WO2009148252A3 true WO2009148252A3 (fr) 2010-05-27

Family

ID=41398661

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/002937 Ceased WO2009148252A2 (fr) 2008-06-02 2009-06-02 Peptide de ciblage d’accident cérébro-vasculaire et applications correspondantes

Country Status (3)

Country Link
US (1) US8748398B2 (fr)
KR (1) KR101110758B1 (fr)
WO (1) WO2009148252A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1937815B1 (fr) * 2005-09-13 2015-05-13 National Research Council of Canada Méthodes et compositions permettant de moduler l'activité des cellules tumorales
PT2504363T (pt) 2009-11-24 2019-08-02 Nat Res Council Canada Anticorpos anticlusterina e fragmentos de ligação ao antigénio e a sua utilização para reduzir o volume de um tumor
CA2862739A1 (fr) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Utilisation conjointe d'un inhibiteur de clusterine et d'un inhibiteur d'egfr pour traiter le cancer
CN103805563B (zh) * 2014-01-23 2015-09-02 浙江大学 一种脑靶向干细胞及其制备方法和应用
EP3130600B1 (fr) 2015-08-14 2019-03-27 Jingyi Wang Composé destiné à traiter les séquelles de l'ictus cérébral ischémique
CN118416253A (zh) * 2024-04-26 2024-08-02 上海市第六人民医院 一种可靶向缺血脑区用于治疗缺血性脑卒中的纳米药物的制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089470A1 (en) * 2003-10-24 2005-04-28 Johnson Bruce F. Labeled peptides for lectin-like oxidized low-density lipoprotein receptor (LOX-1)
KR20080090610A (ko) * 2007-04-05 2008-10-09 경북대학교 산학협력단 동맥경화 진단, 예방 및 치료용 펩타이드 및 이의 용도

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60233949D1 (de) 2001-08-20 2009-11-19 Biosite Inc Diagnostische marker für schlaganfall und hirntrauma sowie verfahren zur verwendung davon

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089470A1 (en) * 2003-10-24 2005-04-28 Johnson Bruce F. Labeled peptides for lectin-like oxidized low-density lipoprotein receptor (LOX-1)
KR20080090610A (ko) * 2007-04-05 2008-10-09 경북대학교 산학협력단 동맥경화 진단, 예방 및 치료용 펩타이드 및 이의 용도

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAI-YAN HONG ET AL.: "Detection of apoptosis in a rat model of focal cerebral ischemia using a homing peptide selected from in vivo phage display", JOURNAL OF CONTROLLED RELEASE, vol. 131, no. 3, 12 November 2008 (2008-11-12), pages 167 - 172 *
HAI-YAN HONG ET AL.: "Phage display selection ofpeptides that home to atherosclerotic plaques : IL-4 receptor as a candidate target in atherosclerosis", JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, vol. 12, no. 5B, 10 December 2007 (2007-12-10), pages 2003 - 2014 *

Also Published As

Publication number Publication date
WO2009148252A2 (fr) 2009-12-10
KR20090125440A (ko) 2009-12-07
KR101110758B1 (ko) 2012-02-15
US8748398B2 (en) 2014-06-10
US20110150764A1 (en) 2011-06-23
WO2009148252A9 (fr) 2010-04-01

Similar Documents

Publication Publication Date Title
WO2008011335A3 (fr) Composés fixant le métal, compositions fixant le métal, ainsi que leurs applications
WO2007149542A3 (fr) Compositions de chémokine microbicide antimicrobiennes et procédés d'utilisation
JP2010534684A5 (fr)
WO2008137758A3 (fr) Lipides d'acides aminés et leurs utilisations
WO2017143042A3 (fr) Compositions permettant d'améliorer l'édition ciblée de gènes et leurs procédés d'utilisation
WO2005023866A3 (fr) Peptides permettant d'inhiber l'activation du complement
WO2010136508A3 (fr) Ciblage de cellules souches
WO2010026010A3 (fr) Agents de traitement capillaire comprenant des oligopeptides faiblement dosés
MY146969A (en) Dpp iv inhibitor formulations
WO2009100263A3 (fr) Produit de soins bucco-dentaires et méthodes d'utilisation et de fabrication dudit produit
EP2384740A3 (fr) Produit de soins oraux et procédés d'utilisation et de fabrication associés
WO2008131150A3 (fr) Nouveaux (méth)acrylates d'uréthanne et leur utilisation dans des compositions de revêtement pouvant durcir
WO2009148252A3 (fr) Peptide de ciblage d’accident cérébro-vasculaire et applications correspondantes
WO2008093060A3 (fr) Peptides et leur utilisation
WO2007112940A3 (fr) Séquence d'acides aminés dérivée de l'albumine, son utilisation pour augmenter la demi-vie de protéines thérapeutiques et d'autres composés et entités thérapeutiques, et produits de recombinaison qui la comprennent
WO2007122581A3 (fr) Compositions et kits utiles dans le traitement de maladies respiratoires
WO2008053297A3 (fr) Compositions pharmaceutiques comprenant l'entacapone, la lévodopa, et la carbidopa
WO2007097903A3 (fr) Peptides inhibiteurs de fusion du vih à propriétés biologiques améliorées
NZ593524A (en) A nonapeptide with anti-tumour activity
NZ606723A (en) Glatiramer acetate molecular weight markers
WO2013093465A3 (fr) Nouvelles formulations
WO2009100275A3 (fr) Compositions et dispositifs
WO2009125409A3 (fr) Amides d'acides gras et leurs utilisations
NZ601142A (en) Composition for improving brain function and method for improving brain function
WO2008073863A3 (fr) Préparation et utilité d'allylamines substituées

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09758505

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12995934

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 09758505

Country of ref document: EP

Kind code of ref document: A2